Ying Lin
Guangzhou University of Chinese Medicine(CN)Office of Education(US)Fujian Medical University(CN)Southwest University of Science and Technology(CN)Nanjing University of Chinese Medicine(CN)Sun Yat-sen University(CN)Jinan University(CN)Northern Arizona University(US)Hainan University(CN)Fudan University(CN)Chinese PLA General Hospital(CN)Fujian Women and Children Hospital(CN)Shenzhen Bay Laboratory(CN)Ningde Normal University(CN)Zhongshan Hospital(CN)Peking University Shenzhen Hospital(CN)The First Affiliated Hospital, Sun Yat-sen University(CN)Fujian Provincial Hospital(CN)Guangdong Academy of Medical Sciences(CN)Third Affiliated Hospital of Sun Yat-sen University(CN)Guangdong Provincial People's Hospital(CN)Union Hospital(CN)Shandong Center for Disease Control and Prevention(CN)Southern Medical University(CN)Fujian Agriculture and Forestry University(CN)Delft University of Technology(NL)
Publications by Year
Research Areas
Cancer Research and Treatments, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Cancer-related molecular mechanisms research, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls Vascular Neointimal Lesion Formation(2009)652 cited
- → Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells(2005)570 cited
- → A Necessary Role of miR-221 and miR-222 in Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia(2009)550 cited
- → Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis(2000)464 cited
- → MicroRNA-21 protects against the H2O2-induced injury on cardiac myocytes via its target gene PDCD4(2009)365 cited
- → ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway(2019)312 cited